149 related articles for article (PubMed ID: 22071989)
21. MiR-126-5p regulates osteoclast differentiation and bone resorption in giant cell tumor through inhibition of MMP-13.
Wu Z; Yin H; Liu T; Yan W; Li Z; Chen J; Chen H; Wang T; Jiang Z; Zhou W; Xiao J
Biochem Biophys Res Commun; 2014 Jan; 443(3):944-9. PubMed ID: 24360951
[TBL] [Abstract][Full Text] [Related]
22. Presence of leukaemia inhibitory factor (LIF) and LIF-receptor chain (gp190) in osteoclast-like cells cultured from human giant cell tumour of bone. Ultrastructural distribution.
Gouin F; Couillaud S; Cottrel M; Godard A; Passuti N; Heymann D
Cytokine; 1999 Apr; 11(4):282-9. PubMed ID: 10328867
[TBL] [Abstract][Full Text] [Related]
23. Downregulation of miR-223 and miR-19a induces differentiation and promotes recruitment of osteoclast cells in giant-cell tumor of the bone via the Runx2/TWIST-RANK/RANKL pathway.
Jiang ZY; Jiang JJ; Ma YS; Li HY; Shi W; Fu PL; Xu CF; Lu JZ; Fu D; Xu JG
Biochem Biophys Res Commun; 2018 Nov; 505(4):1003-1009. PubMed ID: 30309658
[TBL] [Abstract][Full Text] [Related]
24. P2Y2 receptors are expressed by human osteoclasts of giant cell tumor but do not mediate ATP-induced bone resorption.
Bowler WB; Littlewood-Evans A; Bilbe G; Gallagher JA; Dixon CJ
Bone; 1998 Mar; 22(3):195-200. PubMed ID: 9514211
[TBL] [Abstract][Full Text] [Related]
25. PTHrP increases RANKL expression by stromal cells from giant cell tumor of bone.
Cowan RW; Singh G; Ghert M
J Orthop Res; 2012 Jun; 30(6):877-84. PubMed ID: 22102368
[TBL] [Abstract][Full Text] [Related]
26. C/EBPβ mediates osteoclast recruitment by regulating endothelial progenitor cell expression of SDF-1α.
Fu SL; Pang H; Xu JZ; Wu XH
PLoS One; 2014; 9(3):e91217. PubMed ID: 24618682
[TBL] [Abstract][Full Text] [Related]
27. Paclitaxel inhibits osteoclast formation and bone resorption via influencing mitotic cell cycle arrest and RANKL-induced activation of NF-κB and ERK.
Ang ES; Pavlos NJ; Chim SM; Feng HT; Scaife RM; Steer JH; Zheng MH; Xu J
J Cell Biochem; 2012 Mar; 113(3):946-55. PubMed ID: 22034016
[TBL] [Abstract][Full Text] [Related]
28. In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid.
Shibuya I; Takami M; Miyamoto A; Karakawa A; Dezawa A; Nakamura S; Kamijo R
Pathol Oncol Res; 2019 Jan; 25(1):409-419. PubMed ID: 29159783
[TBL] [Abstract][Full Text] [Related]
29. MafB negatively regulates RANKL-mediated osteoclast differentiation.
Kim K; Kim JH; Lee J; Jin HM; Kook H; Kim KK; Lee SY; Kim N
Blood; 2007 Apr; 109(8):3253-9. PubMed ID: 17158225
[TBL] [Abstract][Full Text] [Related]
30. Osteoblast lineage properties in giant cell tumors of bone.
Murata A; Fujita T; Kawahara N; Tsuchiya H; Tomita K
J Orthop Sci; 2005 Nov; 10(6):581-8. PubMed ID: 16307183
[TBL] [Abstract][Full Text] [Related]
31. RANK signalling in bone lesions with osteoclast-like giant cells.
Won KY; Kalil RK; Kim YW; Park YK
Pathology; 2011 Jun; 43(4):318-21. PubMed ID: 21532526
[TBL] [Abstract][Full Text] [Related]
32. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue.
Lau YS; Sabokbar A; Gibbons CL; Giele H; Athanasou N
Hum Pathol; 2005 Sep; 36(9):945-54. PubMed ID: 16153456
[TBL] [Abstract][Full Text] [Related]
33. Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF.
Knowles HJ; Athanasou NA
J Pathol; 2008 May; 215(1):56-66. PubMed ID: 18283716
[TBL] [Abstract][Full Text] [Related]
34. 5-Fluoruracil blocked giant cell tumor progression by suppressing osteoclastogenesis through NF-kappaB signals and blocking angiogenesis.
Song D; Meng T; Xu W; Hou T; Lin Z; Yin H; Li B; Zhou L; Wang T; Han S; Fan T; Miao W; Liu M; Luo J; Zhou W; Li Z; Xiao J
Bone; 2015 Sep; 78():46-54. PubMed ID: 25956534
[TBL] [Abstract][Full Text] [Related]
35. Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB.
Morgan T; Atkins GJ; Trivett MK; Johnson SA; Kansara M; Schlicht SL; Slavin JL; Simmons P; Dickinson I; Powell G; Choong PF; Holloway AJ; Thomas DM
Am J Pathol; 2005 Jul; 167(1):117-28. PubMed ID: 15972958
[TBL] [Abstract][Full Text] [Related]
36. Sustained autocrine induction and impaired negative feedback of osteoclastogenesis in CD14(+) cells of giant cell tumor of bone.
Avnet S; Salerno M; Zini N; Alberghini M; Gibellini D; Baldini N
Am J Pathol; 2013 Apr; 182(4):1357-66. PubMed ID: 23395086
[TBL] [Abstract][Full Text] [Related]
37. Gene expression of transforming growth factor-beta 1 and its type II receptor in giant cell tumors of bone. Possible involvement in osteoclast-like cell migration.
Zheng MH; Fan Y; Wysocki SJ; Lau AT; Robertson T; Beilharz M; Wood DJ; Papadimitriou JM
Am J Pathol; 1994 Nov; 145(5):1095-104. PubMed ID: 7977641
[TBL] [Abstract][Full Text] [Related]
38. Breast cancer cell line MDA-231 stimulates osteoclastogenesis and bone resorption in human osteoclasts.
Grano M; Mori G; Minielli V; Cantatore FP; Colucci S; Zallone AZ
Biochem Biophys Res Commun; 2000 Apr; 270(3):1097-100. PubMed ID: 10772956
[TBL] [Abstract][Full Text] [Related]
39. CCAAT/enhancer-binding protein beta inhibits proliferation in monocytic cells by affecting the retinoblastoma protein/E2F/cyclin E pathway but is not directly required for macrophage morphology.
Gutsch R; Kandemir JD; Pietsch D; Cappello C; Meyer J; Simanowski K; Huber R; Brand K
J Biol Chem; 2011 Jul; 286(26):22716-29. PubMed ID: 21558273
[TBL] [Abstract][Full Text] [Related]
40. Aminothiazoles inhibit osteoclastogenesis and PGE
Kats A; Gerasimcik N; Näreoja T; Nederberg J; Grenlöv S; Lagnöhed E; Desai S; Andersson G; Yucel-Lindberg T
J Cell Mol Med; 2019 Feb; 23(2):1152-1163. PubMed ID: 30506812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
